Cell Disease
Most patients with sickle cell disease not prescribed disease-modifying therapy
The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according to an analysis of real-world data.
ASH honors two individuals for sickle cell disease advocacy efforts
American Society of Hematology presented Advocacy Awards to two individuals at this year’s ASH Annual Meeting.
Novel cell therapy ‘potentially life changing’ for people with sickle cell disease
SAN DIEGO — An investigational cell therapy reduced sickle hemoglobin and increased fetal and total hemoglobin for certain patients with sickle cell disease, according to results presented at ASH Annual Meeting and Exposition.
Consensus statement helps assess patient readiness for gene therapy in sickle cell disease
Patient readiness will greatly affect the success of gene therapy for sickle cell disease at the individual and collective levels, according to a consensus statement published in JAMA Network Open.
Study: Most US newborns with sickle cell disease are born in vulnerable areas
About two-thirds of newborns with sickle cell disease in the United States are born to mothers who live in counties with high or very high levels of social vulnerability, according to research findings published in MMWR.
People with sickle cell disease seldom receive newer pain medications
Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.
National registry may reduce mortality among alloimmunized people with sickle cell disease
A nationwide red blood cell alloantibody exchange could reduce mortality among alloimmunized individuals with sickle cell disease, according to study results presented at ASH Annual Meeting and Exposition.